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ABSTRACT
Here, we employed a bioinformatics approach to identify novel molecular 
determinants to predict tumor progression and overall survival in gastric cancer 
patients. In particular, we directly assessed whether nuclear-derived mRNA species 
encoding proteins involved in mitochondrial protein translation and OXPHOS are able 
to successfully predict clinical outcome in gastric cancer. As such, using in silico 
validation, we have now established the prognostic value of these mitochondrial 
biomarkers, in a defined population of gastric cancer patients. In this context, we 
interrogated 5 year follow-up data collected from a group of N = 359 gastric cancer 
patients. Importantly, in this group of cancer patients, Ki67 and PCNA (conventional 
markers of cell proliferation) were associated with tumor progression, as might 
be expected. Using this simplified informatics approach, we identified ~75 new 
individual mitochondrial gene probes that effectively predicted tumor progression, 
with hazard-ratios (HR) of up to 2.22 (p < 2.1e-10). These mitochondrial mRNA 
transcripts included heat shock proteins/chaperones, membrane proteins, anti-
oxidants, enzymes involved in genome maintenance, as well as mitochondrial 
ribosomal proteins (MRPs) and numerous members of the OXPHOS complexes. In 
addition, we combined 8 mitochondrial protein transcripts (NDUFS5, VDAC3, ATP5O, 
IMMT, MRPL28, COX5B, MRPL52, PRKDC), to generate a compact gastric mitochondrial 
gene signature, associated with a HR of 2.77 (p = 1.4e-14). As a result of this analysis 
and validation, we strongly suggest that proteins involved in mitochondrial protein 
translation and OXPHOS should be considered as targets for new drug discovery, for 
the treatment of gastric cancers. The mitochondrial markers we identified here could 
also be used as companion diagnostics, to predict clinical outcomes, as well as the 
patient response to therapy. This should allow a more successful and personalized 
approach to gastric cancer diagnosis and therapy.
INTRODUCTION
Gastric cancer, also known as stomach cancer, 
starts as an infectious disease that drives the development 
of chronic inflammation and ulcerated lesions, located 
within the stomach wall lining. In most cases of gastric 
cancer, these lesions are morphologically defined as 
epithelial carcinomas [1-3]. During tumor progression, the 
gastric cancer cells migrate and metastasize to the lymph 
nodes, the abdomen, bones, lungs and the liver. The most 
common etiology of gastric cancer is chronic infection 
with Helicobacter pylori, a bacterium, which represents 
~50-70% of the cases [4-6]. Classic symptoms consist of 
“heartburn”, abdominal pain, nausea and vomiting, as well 
as anemia and occult blood in the feces. The diagnosis 
of gastric cancer is confirmed by an endoscopic biopsy, 
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revealing an invasive carcinoma. The disease is most 
common in Asian countries, especially in South Korea and 
Japan, among others [1-6]. 
Unfortunately, the 5-year survival rates for gastric 
cancer patients vary widely, from as low as 15% to as high 
as 60%. As such, more effective biomarkers are urgently 
needed for the early stratification of gastric cancer 
patients, into low-risk and high-risk groups at diagnosis. 
Here, we directly tested the hypothesis that markers of 
mitochondrial biogenesis and respiratory function may 
have significant prognostic value in the early identification 
of high-risk gastric cancer patients, with increased tumor 
progression and poor overall survival. 
More specifically, we employed a bioinformatics 
approach to determine the prognostic utility of nuclear-
encoded mitochondrial mRNA species in predicting 
clinical outcome. Our results indicate that ~75 individual 
mitochondrial gene probes can be effectively used, to 
predict progression and survival in gastric cancer patients. 
As a result, we propose the idea that mitochondria are 
novel therapeutic targets for drug discovery, aimed at 
optimizing the effectiveness of gastric cancer therapy [7-
9]. 
RESULTS
Prognostic value of proliferative and 
inflammatory markers in gastric cancer patients
Here, we used publically available transcriptional 
profiling data from the tumors of gastric cancer patients, 
with 5 years of follow-up data, to identify new potential 
biomarkers (Figure 1). As proliferative biomarkers are 
often used as clinical endpoints in patient trials, we first 
assessed the prognostic value of Ki67 and PCNA, in this 
patient population. Tables 1, 2 and Figure 2 both show the 
prognostic value of these markers. The hazard-ratios for 
Ki67 and PCNA were 1.79 and 1.86, respectively, for time 
to first progression (FP). 
We also assessed the prognostic value of a 
macrophage-specific marker of inflammation, namely 
CD163. Table 2 and Figure 2 show that CD163 effectively 
predicted time to first progression, with a hazard-ratio of 
1.46. Thus, conventional markers of proliferation and 
inflammation predict overall survival in gastric cancer 
patients.
Prognostic value of individual mitochondrial 
markers
To evaluate the hypothesis that elevated 
mitochondrial mass, biogenesis and function somehow 
contributes towards poor clinical outcome in gastric 
cancer patients, we also determined the prognostic value 
of individual mitochondrial markers. 
First, we examined the behavior of mitochondrial 
membrane proteins and HSPs/chaperones. Table 3 and 
Figure 3 both show that VDAC3 and IMMT had the 
best prognostic value, with a hazard-ratio of up to 2.22 
(p<1.4e-09). HSPD1 and members of the TIMM and 
TOMM gene families also had prognostic value; SOD2 
also had significant value. Positive results were also 
obtained with DNA-PK (PRKDC), a kinase that maintains 
Figure 1: A bio-informatics approach to gastric cancer marker discovery. We chose to focus on gastric cancer patients, with 
5-years of follow-up data (N = 359). In this context, we evaluated the prognostic value of mitochondrial markers for predicting time to first 
progression and overall survival. 
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Table 1: Prognostic value of Ki67 in gastric cancer
Table 2: Prognostic value of PCNA and CD163 in gastric cancer
Table 3: Prognostic value of mitochondrial HSPs and other mitochondrial proteins
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Figure 2: Markers of proliferation and inflammation predict poor clinical outcome in gastric cancer patients. We 
assessed the predictive value of Ki67 and PCNA in N = 359 gastric cancer patients. A. Note that high transcript levels of Ki67 and PCNA 
are associated with significantly reduced time to first progression. Note that the official gene name for the Ki67 protein is MKI67. B. Note 
that that high transcript levels of CD163 are associated with significantly reduced time to first progression.
Figure 3: Mitochondrial membrane proteins and PRKDC are associated with poor clinical outcome in gastric cancer 
patients. A. Note that that high transcript levels of VDAC3 and IMMT are associated with significantly reduced time to first progression. 
B. Note that that high transcript levels of PRKDC are associated with significantly reduced time to first progression.
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Figure 4: Mitochondrial ribosomal proteins (MRPs) are associated with poor clinical outcome in gastric cancer 
patients. A. Note that high transcript levels of MRPL28 and MRPL52 predict significantly reduced time to first progression. B. Similarly, 
high transcript levels of MRPS11 and MRPS12 predict significantly reduced time to first progression.
Figure 5: Mitochondrial complex I and II proteins are associated with poor clinical outcome in gastric cancer patients. 
A. Note that high levels of NDUFS5 and NDUFA5 predict significantly reduced time to first progression. B. Similarly, high levels of SDHB 
predict significantly reduced time to first progression.
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the integrity and copy number of the mitochondrial 
genome (mt-DNA). 
Next, we determined the prognostic value of 
mitochondrial ribosomal proteins (MRPs), which 
are essential for mitochondrial biogenesis (Table 4). 
Twelve components of the large subunit (MRPLs) 
showed significant prognostic value, with hazard-ratios 
between 2.17 and 1.29. Notably, MRPL28 had the best 
prognostic value. Eight different components of the small 
subunit (MRPSs) showed significant prognostic value, 
with hazard-ratios between 1.89 and 1.36. As a result, 
twenty different MRPs all predicted reduced time to first 
progression. Representative examples of Kaplan-Meier 
curves are shown in Figure 4, panels A & B.
In addition, we evaluated the prognostic value of 
members of the OXPHOS complexes I-V. These results 
are summarized in Table 5. Interestingly, 37 different gene 
probes for the OXPHOS complexes showed hazard-ratios 
between 2.27 and 1.30. NDUFS5 (complex I) had the best 
prognostic value (HR=2.27; p=6e-10). COX5B (complex 
IV) and ATP5O (complex V) also showed significant 
prognostic value (HR=2.14; p=1.4e-08 versus HR=2.22; 
p=2.1e-10). Kaplan-Meier analysis for components 
of complex I and II are shown in Figure 5A, 5B, while 
results with complex III and IV are shown in Figure 6A, 
6B. Results with complex V are highlighted in Figure 7.
Prognostic value of a short gastric (Ga) mito-
signature
To increase the prognostic significance of these 
unique mitochondrial markers, we then combined the most 
promising markers to create a new gastric mitochondrial 
gene signature. 
More specifically, Ga-Mito-Signature-1 contains 
8 genes (NDUFS5, VDAC3, ATP5O, IMMT, MRPL28, 
COX5B, MRPL52, PRKDC). Importantly, Ga-Mito-
Signature-1 yielded a significantly improved hazard-ratio 
for time to first progression (FP) (HR=2.77; p=1.4e-14), 
as well as for overall survival (OS) (HR=2.01; p=6e-11). 
These results are summarized in Table 6 and highlighted 
in Figure 8. 
As such, the Ga-Mito-Signature-1 represents a 
significant improvement over individual mitochondrial 
biomarkers, as well as Ki67 and PCNA.
Table 4: Prognostic value of mitochondrial ribosomal proteins
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Table 5: Prognostic value of mitochondrial OXPHOS complexes
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DISCUSSION
New “druggable” targets for inhibiting 
mitochondrial biogenesis and blocking oxidative 
metabolism in cancer cells
Here, we suggest that the new mitochondrial 
markers that we developed here may also be useful for 
selecting new “druggable” targets for innovative drug 
development, to prevent treatment failure and improve 
overall survival. As a consequence of our K-M analyses, 
we believe that the mitochondrial ribosome would be an 
attractive new target for developing novel inhibitors of 
mitochondrial protein translation in cancer cells; similarly, 
mitochondrial chaperones, the OXPHOS complexes and 
the mitochondrial ATP-synthase may also be suitable 
drug targets. Particular components of these multi-subunit 
protein complexes show significant prognostic value, 
Table 6: Compact gastric CA mito-signature for predicting clinical outcome
Figure 6: Mitochondrial complex III and IV proteins are associated with poor clinical outcome in gastric cancer 
patients. A. Note that high levels of BCS1L and UQCR8 predict significantly reduced time to first progression. B. Similarly, high levels 
of COX5B and COX4NB predict reduced time to first progression.
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Figure 8: A short mitochondrial signature predicts tumor progression and overall survival in gastric cancer patients. 
We combined 8 mitochondrial proteins (NDUFS5, VDAC3, ATP5O, IMMT, MRPL28, COX5B, MRPL52, PRKDC), to generate a compact 
gastric mitochondrial gene signature.
Figure 9: Gastric cancer: Mitochondrial-based 
diagnostics for personalized therapy. In this proposed 
scheme, mitochondrial markers could be used to separate gastric 
cancer patients into high-risk and low-risk groups. Then, patients 
with high levels of mitochondrial markers in their primary tumor 
(“bad prognosis”) would be treated with mitochondrial-based 
therapies, to prevent progression and increase survival.
Figure 7: Mitochondrial complex V proteins are associated with poor clinical outcome in gastric cancer patients. Note 
that high levels of ATP5O and ATP5G2 predict significantly reduced time to first progression.
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suggesting that modulation of their intrinsic activity may 
provide therapeutic benefits. Targeting of these large 
protein complexes would be predicted to suppress tumor 
recurrence and prevent disease progression in these gastric 
cancer patients. 
Similarly, these mitochondrial markers could also be 
employed as companion diagnostics for novel therapies 
targeting either mitochondrial protein translation or 
cellular respiration, to select the high-risk sub-population 
of gastric cancer patients, resulting in the proper treatment 
stratification (Figure 9). In direct support of this assertion, 
we showed here that ~75 different mitochondrial probes 
could be used to successfully identify the sub-population 
of high-risk gastric cancer patients. As such, these results 
indicate that mitochondrial markers could be used to 
monitor and/or predict the response to therapy, identifying 
patients at high-risk for treatment failure at diagnosis, 
several years in advance, even prior to the initiation of 
therapy.
Cancer stem cells (CSCs) have increased 
mitochondrial power: diagnostic and therapeutic 
implications
Recently, we identified increased mitochondrial 
function as a new feature of cancer stem cells (CSCs), 
based on unbiased proteomics analysis [7-9,11]. This 
increase is mitochondrial function in CSCs may be 
secondary to increased mitochondrial biogenesis and/or 
elevated mitochondrial protein translation, resulting in the 
steady-state amplification of mitochondrial mass [7-9,11]. 
These findings have important implications for designing 
new approaches for identifying and eradicating CSCs. 
Importantly, our previous studies directly show 
that MitoTracker (a fluorescent mitochondrial vital dye) 
can be used, together with flow cytometry, to purify 
CSCs from heterogeneous populations of cancer cells 
[12,13]. Importantly, the “Mito-high” cells showed the 
greatest functional capacity for i) anchorage-independent 
growth and ii) tumor-initiating activity in vivo [12-14]. 
Quantitatively similar results were also obtained with 
other mitochondrial probes (for detecting ROS and H2O2) 
and/or NAD(P)H auto-fluorescence, all surrogate markers 
of increased mitochondrial respiratory activity [14]. 
In support of these functional studies, we have also 
shown that FDA-approved antibiotics can be used to 
effectively target mitochondria in CSCs [15-21]. Because 
mitochondria evolved from aerobic bacteria, over a period 
>1.5 billion years, certain types of antibiotics functionally 
inhibit mitochondrial biogenesis, as a manageable side-
effect. In this context, tetracycline antibiotics, such as 
Doxycycline, appeared to be the most promising. For 
example, Doxcycline effectively eradicates CSCs in 12 
different cell lines, representing 8 different cancer types, 
as well as in primary tissue samples derived from patients 
with advanced metastatic disease (collected from pleural 
effusions or ascites fluid) [15,16].
Interestingly, these functional observations could 
mechanistically explain the high prognostic value of 
mitochondrial markers in predicting progression and 
survival in gastric cancer patients. Patients with high 
levels of mitochondrial markers may have increased 
levels of CSCs (Figure 9). As a result, these mitochondrial 
biomarkers could also be used as companion diagnostics, 
to identify which gastric cancer patients would benefit 
most from anti-cancer therapy with Doxycycline (or 
perhaps with other inhibitors of mitochondrial biogenesis 
and/or drugs metabolically targeting respiratory function, 
such as Metformin). 
METHOD OF ANALYSIS
Kaplan-Meier (K-M) Analyses. To perform K-M 
analysis on nuclear mitochondrial gene transcripts, we 
used an open-access, online survival, data analysis tool to 
interrogate publically available microarray data from up 
to 1,065 gastric cancer patients [10]. This allowed us to 
determine their overall prognostic value. For this purpose, 
we primarily analyzed 5-year follow-up data from gastric 
cancer patients (N = 359). Biased array data were excluded 
from the analysis. This allowed us to identify ~75 nuclear 
mitochondrial gene probes, with significant prognostic 
value. Hazard-ratios for time to first progression (FP) 
and overall survival (OS) were calculated, at the best 
auto-selected cut-off, and p-values were calculated using 
the logrank test and plotted in R. K-M curves were also 
generated online using the K-M-plotter (as high-resolution 
TIFF files) [10], using univariate analysis: 
http://kmplot.com/analysis/index.
php?p=service&cancer=gastric
This allowed us to directly perform in silico 
validation of these mitochondrial biomarker candidates. 
Abbreviations
CSCs, cancer stem-like cells; HR, hazard ratio; 
K-M, Kaplan-Meier; MRPL, mitochondrial ribosomal 
proteins, large subunit; MRPS, mitochondrial ribosomal 
proteins, small subunit; N, number of patients in a given 
data set; OS, overall survival; OXPHOS, oxidative 
phosphorylation (mitochondrial respiration); FP, time to 
first progression
Author contributions
Professor Lisanti and Dr. Sotgia conceived and 
initiated this project. Professor Lisanti and Dr. Sotgia 
both performed the bioinformatics analysis, and wrote the 
manuscript. 
Oncotarget67127www.impactjournals.com/oncotarget
FUNDING
It should be noted that this bioinformatics analysis, 
focused on nuclear-encoded mitochondrial-related gene 
transcripts, was not funded by a specific grant and did 
not require any research expenditures, since no “wet” 
laboratory experiments were performed. 
CONFLICTS OF INTEREST
MPL and FS hold a minority interest in Lunella, Inc.
REFERENCES
1. Luo G, Hu Y, Zhang Z, Wang P, Luo Z, Lin J, Cheng C, 
Yang Y. Clinicopathologic significance and prognostic 
value of Ki-67 expression in patients with gastric cancer: 
a meta-analysis. Oncotarget. 2017; 8: 50273-50283. https://
doi.org/10.18632/oncotarget.17305. 
2. Machairas N, Charalampoudis P, Molmenti EP, Kykalos S, 
Tsaparas P, Stamopoulos P, Sotiropoulos GC. The value of 
staging laparoscopy in gastric cancer. Ann Gastroenterol. 
2017; 30: 287-294. 
3. Reid BJ. Genomics, Endoscopy, and Control of 
Gastroesophageal Cancers: A Perspective. Cell Mol 
Gastroenterol Hepatol. 2017;3: 359-366. 
4. Liu X, Meltzer SJ. Gastric Cancer in the Era of Precision 
Medicine. Cell Mol Gastroenterol Hepatol. 2017; 3: 348-
358. 
5. Hayakawa Y, Fox JG, Wang TC. The Origins of Gastric 
Cancer From Gastric Stem Cells: Lessons From Mouse 
Models. Cell Mol Gastroenterol Hepatol. 2017; 3: 331-338. 
6. Shimizu D, Kanda M, Kodera Y. Review of recent 
molecular landscape knowledge of gastric cancer. Histol 
Histopathol. 2017; 27: 11898. 
7. Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, 
Sotgia F, Lisanti MP. Cancer stem cell metabolism. Breast 
Cancer Res. 2016; 18: 55. 
8. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, 
Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic 
perspective. Nat Rev Clin Oncol. 2017; 14: 11-31.
9. Killock D. Drug therapy: Can the mitochondrial adverse 
effects of antibiotics be exploited to target cancer 
metabolism? Nat Rev Clin Oncol. 2015; 12: 190. 
10. Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, 
Green JE, Boussioutas A, Busuttil R, Szabó A, Győrffy 
B. Cross-validation of survival associated biomarkers in 
gastric cancer using transcriptomic data of 1,065 patients. 
Oncotarget. 2016; 7: 49322-33. https://doi.org/10.18632/
oncotarget.10337. 
11. Lamb R, Harrison H, Hulit J, Smith DL, Lisanti MP, Sotgia 
F. Mitochondria as new therapeutic targets for eradicating 
cancer stem cells: Quantitative proteomics and functional 
validation via MCT1/2 inhibition. Oncotarget. 2014; 5: 
11029-37. https://doi.org/10.18632/oncotarget.2789.
12. Farnie G, Sotgia F, Lisanti MP. High mitochondrial mass 
identifies a sub-population of stem-like cancer cells that are 
chemo-resistant. Oncotarget. 2015; 6: 30472-86. https://doi.
org/10.18632/oncotarget.5401.
13. Lamb R, Bonuccelli G, Ozsvári B, Peiris-Pagès M, Fiorillo 
M, Smith DL, Bevilacqua G, Mazzanti CM, McDonnell LA, 
Naccarato AG, Chiu M, Wynne L, Martinez-Outschoorn 
UE, et al. Mitochondrial mass, a new metabolic biomarker 
for stem-like cancer cells: Understanding WNT/FGF-driven 
anabolic signaling. Oncotarget. 2015; 6: 30453-71. https://
doi.org/10.18632/oncotarget.5852.
14. Bonuccelli G, De Francesco EM, de Boer R, Tanowitz 
HB, Lisanti MP. NADH autofluorescence, a new 
metabolic biomarker for cancer stem cells: Identification 
of Vitamin C and CAPE as natural products targeting 
“stemness”. Oncotarget. 2017; 8: 20667-20678. https://doi.
org/10.18632/oncotarget.15400.
15. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, 
Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Antibiotics 
that target mitochondria effectively eradicate cancer stem 
cells, across multiple tumor types: Treating cancer like an 
infectious disease. Oncotarget. 2015; 6: 4569-84. https://
doi.org/10.18632/oncotarget.3174.
16. Lamb R, Fiorillo M, Chadwick A, Ozsvari B, Reeves KJ, 
Smith DL, Clarke RB, Howell SJ, Cappello AR, Martinez-
Outschoorn UE, Peiris-Pagès M, Sotgia F, Lisanti MP. 
Doxycycline down-regulates DNA-PK and radiosensitizes 
tumor initiating cells: Implications for more effective 
radiation therapy. Oncotarget. 2015; 6: 14005-25.  https://
doi.org/10.18632/oncotarget.4159.
17. Bonuccelli G, Peiris-Pages M, Ozsvari B, Martinez-
Outschoorn UE, Sotgia F, Lisanti MP. Targeting cancer 
stem cell propagation with palbociclib, a CDK4/6 
inhibitor: Telomerase drives tumor cell heterogeneity. 
Oncotarget. 2017; 8: 9868-84. https://doi.org/10.18632/
oncotarget.14196.
18. De Luca A, Fiorillo M, Peiris-Pagès M, Ozsvari B, Smith 
DL, Sanchez-Alvarez R, Martinez-Outschoorn UE, 
Cappello AR, Pezzi V, Lisanti MP, Sotgia F. Mitochondrial 
biogenesis is required for the anchorage-independent 
survival and propagation of stem-like cancer cells. 
Oncotarget. 2015; 6: 14777-95. https://doi.org/10.18632/
oncotarget.4401.
19. Fiorillo M, Lamb R, Tanowitz HB, Cappello AR, Martinez-
Outschoorn UE, Sotgia F, Lisanti MP. Bedaquiline, an 
FDA-approved antibiotic, inhibits mitochondrial function 
and potently blocks the proliferative expansion of stem-like 
cancer cells (CSCs). Aging (Albany NY). 2016; 8: 1593-
607. https://doi.org/10.18632/aging.100983.
20. Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-
Demonacos M, Cappello AR, Martinez-Outschoorn UE, 
Sotgia F, Lisanti MP. Repurposing Atovaquone: Targeting 
Oncotarget67128www.impactjournals.com/oncotarget
mitochondrial complex III and OXPHOS to eradicate 
cancer stem cells. Oncotarget. 2016; 7: 34084-99. https://
doi.org/10.18632/oncotarget.9122.
21. Fiorillo M, Sotgia F, Sisci D, Cappello AR, Lisanti MP. 
Mitochondrial “power” drives tamoxifen resistance: NQO1 
and GCLC are new therapeutic targets in breast cancer. 
Oncotarget, 2017; 8: 20309-327. https://doi.org/10.18632/
oncotarget.15852.
